A Phase 1 interventional study of AZD5004 in Hepatic Impairment, sponsored by AstraZeneca. Completed at 5 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-15.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.
This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, or severe hepatic impairment compared with participants with normal hepatic function.
Participants will be enrolled within the following groups based on their Child Pugh classification score as determined at screening:
Group 1: Participants with mild hepatic impairment (Child Pugh Class A, score of 5 or 6).
Group 2: Participants with moderate hepatic impairment (Child Pugh Class B, score of 7 to 9).
Group 3: Participants with severe hepatic impairment (Child Pugh Class C, score of 10 to 15).
Group 4: Participants with normal hepatic function matched on a group level regarding sex, age, and body weight to the impaired participants.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For ALL participants:
For Healthy Controls:
-Participant must be medically healthy with no significant findings on medical evaluation at screening to include but not limited to an >90 ml/min/1.73 m2
For participants with hepatic impairment:
Exclusion Criteria:
For ALL participants:
Specific For Healthy Controls:
-Positive screening for , , or -
-Any clinically significant disease or disorder to include but not limited to acute or chronic liver disease
Specific For Hepatically Impaired Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single oral dose of AZD5004 under fasted conditions.
Drug: AZD5004
A single oral dose of AZD5004 under fasted conditions.
Drug: AZD5004
A single oral dose of AZD5004 under fasted conditions.
Drug: AZD5004
A single oral dose of AZD5004 under fasted conditions.
Drug: AZD5004
Dose 1
Also known as: ECC5004, Dose 1
AUCinf
Area under plasma concentration-time curve from zero to infinity
Time frame: Day 1 to Day 6
AUClast
Area under plasma concentration-time curve from time zero to the last measurable concentration
Time frame: Day 1 to Day 6
Cmax
Maximum observed plasma concentration
Time frame: Day 1 to Day 6
Tmax
Time to reach maximum observed plasma concentration
Time frame: Day 1 to Day 6
PK parameters (t1/2λz)
Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve
Time frame: Day 1 to Day 6
PK parameters CL/F
Apparent total body clearance of drug from plasma after extravascular administration
Time frame: Day 1 to Day 6
PK parameters CLNR/F
Non-renal clearance of drug from plasma after oral administration
Time frame: Day 1 to Day 6
PK parameter Vz/F
Apparent volume of distribution during the terminal phase after extravascular administration
Time frame: Day 1 to Day 6
PK parameter CLr
Renal clearance of the drug from plasma
Time frame: Day 1 to Day 6
PK parameter Ae
Cumulative amount of unchanged drug excreted into the urine
Time frame: Day 1 to Day 6
fe
Fraction of the drug excreted into the urine
Time frame: Day 1 to Day 6
Number of participants with adverse events (AEs)
To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function
Time frame: Day 1 to Day 10
Participants with abnormal blood pressure
To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function
Time frame: Day 1 to Day 6
Number of participants with abnormal laboratory tests results
To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function
Time frame: Day 1 to Day 6
Number of participants with serious adverse events (SAEs)
To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function
Time frame: Day 1 to Day 10
Participants with abnormal ECG QTcF findings
To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function
Time frame: Day 1 to Day 6
Participants with abnormal physical examination findings
To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function
Time frame: Day 1 to Day 6
Participants with abnormal heart rate
To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function
Time frame: Day 1 to Day 6
Number of participants with abnormal ECG PR interval findings
To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function
Time frame: Day 1 to Day 6
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Oct 2025, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elecoglipron